Tappia Paramjit S
Institute of Cardiovascular Sciences, St. Boniface General Hospital Research Centre and Department of Human Nutritional Sciences, University of Manitoba, Winnipeg, MB, R2H 2A6, Canada.
Can J Physiol Pharmacol. 2007 Jan;85(1):25-41. doi: 10.1139/y06-098.
The phospholipases associated with the cardiac sarcolemmal (SL) membrane hydrolyze specific membrane phospholipids to generate important lipid signaling molecules, which are known to influence normal cardiac function. However, impairment of the phospholipases and their related signaling events may be contributory factors in altering cardiac function of the diseased myocardium. The identification of the changes in such signaling systems as well as understanding the contribution of phospholipid-signaling pathways to the pathophysiology of heart disease are rapidly emerging areas of research in this field. In this paper, I provide an overview of the role of phospholipid-mediated signal transduction processes in cardiac hypertrophy and congestive heart failure, diabetic cardiomyopathy, as well as in ischemia-reperfusion. From the cumulative evidence presented, it is suggested that phospholipid-mediated signal transduction processes could serve as novel targets for the treatment of the different types of heart disease.
与心肌肌膜（SL）相关的磷脂酶可水解特定的膜磷脂，生成重要的脂质信号分子，已知这些分子会影响正常心脏功能。然而，磷脂酶及其相关信号事件的受损可能是导致患病心肌心脏功能改变的因素。识别此类信号系统的变化以及了解磷脂信号通路对心脏病病理生理学的作用，是该领域迅速兴起的研究方向。在本文中，我概述了磷脂介导的信号转导过程在心肌肥大、充血性心力衰竭、糖尿病性心肌病以及缺血再灌注中的作用。根据所提供的累积证据，表明磷脂介导的信号转导过程可作为治疗不同类型心脏病的新靶点。
